Eyevensys announced it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to advance its technology into clinical development. Eyevensys is developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, according to a company news release.
The EyeCET platform uses Eyevensys’ proprietary electro-transfection injection system (ETIS) to deliver plasmids that encode for the production of disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product, EYS606, uses a plasmid encoding for the production of anti-TNFα for the treatment of noninfectious uveitis. EYS606 has been granted an orphan drug designation by the EMA for the treatment of noninfectious uveitis.
“We are pleased the MHRA has approved our unique technology to enter into clinical development in the UK," Raffy Kazandjian, CEO of Eyevensys, said in the news release. "This validation is another commitment of EYS606 alongside the ANSM approval. We are now all set up to demonstrate that our technology can provide much better outcomes for patients with ophthalmology diseases that need improved treatment options.”